5S,12R,18R- trihydroxy- 6Z,8E,10E,14Z,16E- eicosapentaenoic acid

05/01/2014 - "RvE1 was more effective in reducing inflammation at earlier stages. "
01/01/2014 - "RvE1 is locally generated in response to inflammation where it enhances the resolution phase of inflammation by diminishing neutrophil chemotaxis and by enhancing nonphlogistic macrophage-directed clearance of apoptotic neutrophils. "
09/10/2010 - "RvE1 treatment at the time of either OVA sensitization or challenge also improved AHR and airway inflammation. "
01/01/2021 - "In this study, we hypothesized that the RvE1 would restore homeostatic balance and inflammation by targeting the Th17 function. "
01/01/2010 - "The aim of this study was to determine whether RvE1 regulates colonic inflammation when the innate immune response of macrophages plays a key role in pathogenesis and tissue damage. "

01/01/2022 - "One study evaluated the influence of RvE1 topical application on both the prevention and treatment of experimental periodontitis. "
01/01/2021 - "In the present study, we studied the impact of RvE1 on the gingival inflammatory infiltrate formation during periodontitis in a mouse model. "
01/01/2022 - "Corrigendum: RvE1 Impacts the Gingival Inflammatory Infiltrate by Inhibiting the T Cell Response in Experimental Periodontitis."
01/01/2021 - "RvE1 Impacts the Gingival Inflammatory Infiltrate by Inhibiting the T Cell Response in Experimental Periodontitis."
10/01/2016 - "Treatment of established periodontitis with RvE1 reversed bone loss, reversed inflammatory gene expression, and reduced osteoclast density. "

10/16/2018 - "This study identifies 18-monohydroxy EPA as a major plasma marker after EPA supplementation and demonstrates that the ERV1/ChemR23 receptor for its downstream mediator resolvin E1 transduces protective effects in atherosclerosis. "
01/01/2019 - "RvE1 reduces atherosclerosis and intimal hyperplasia by means of its specific receptor ERV1/ChemR23. "
05/01/2015 - "RvE1, used as an oral/topical agent, significantly diminished atherogenesis and prevented periodontitis (P<0.05). "
05/01/2015 - "Here, we determined whether oral/topical application of RvE1 attenuates aortic atherosclerosis induced by both diet and periodontal inflammation. "
08/01/2008 - ""Pro-resolution" and anti-inflammation, a role of RvE1 in anti-atherosclerosis and plaque stabilization."

11/01/2012 - "Resolvin E1 (RX-10001) reduces corneal epithelial barrier disruption and protects against goblet cell loss in a murine model of dry eye."
11/01/2012 - "Based on its proven efficacy in models of chronic inflammation, this study investigated the efficacy of resolvin E1 in a murine model of dry eye. "
03/01/2011 - "This is supported in a study in which topical RvE1 resulted in decreased inflammation in a mouse dry eye model. "
10/01/2010 - "Resolvin E1 improves tear production and decreases inflammation in a dry eye mouse model."
11/01/2012 - "RvE1, delivered as its methyl ester prodrug, improved the outcome measures of corneal staining and goblet cell density in this murine model of dry eye, indicating the potential utility of endogenous resolvins and resolvin analogues in the treatment of dry eye."

08/10/2010 - "Compared with vehicle controls, administration of RvE1 resulted in significant improvement of disease activity indices (e.g., body weight, colon length) concomitant with increased ALPI expression in the intestinal epithelium. "
10/11/2023 - "Over the course of pregnancy, the levels of protection (PDX), maresin, resolvins (RvD1, RvE1), and their precursors differed in relation to the trimester of pregnancy and the division into groups considering the correct body weight before pregnancy. "
10/09/2017 - "In gain-of-function studies using mice overexpressing the human resolvin E1 receptor (ERV1) in myeloid cells, monocyte phenotypic shifts to increased patrolling-to-inflammatory ratio controlled inflammation, reduced body weight gain and protected from hyperglycemia on high-fat diet. "
01/01/2019 - "Compared to CD, HFD induced body weight gain, liver steatosis and TG accumulation, with up-regulation of proinflammatory markers in the absence of histological inflammation or serum AST changes; these results were accompanied by higher hepatic levels of resolvins RvE1, RvE2, RvD1 and RvD2, with decreases in EPA and DHA contents. "
11/22/2020 - "Male Sprague-Dawley rats received diethylnitrosamine (DEN, 70 mg/mg body weight intraperitoneally (i.p)) as an inductor of liver fibrosis once weekly and RvE1(100 ng/body weight i.p) twice weekly for four weeks. "